2871 results
SGLT2 Inhibitors and Cardiovascular Pathophysiology

#SGLT2i #Inhibitors #Cardiovascular #Pathophysiology
SGLT2 Inhibitors ... Pathophysiology #SGLT2i
Echocardiogram and POCUS Cardiology Windows and Anatomy
 • Parasternal Long Axis (PLAX)
 • Subcostal 4 Chamber
Echocardiogram and POCUS Cardiology ... Subcostal 4 Chamber (S4C ... Apical 4 Chamber (A4C ... Apical 2 Chamber (A2C ... Echocardiogram #POCUS #Cardiology
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... risk; signal for SGLT2i ... outcomes trial in SGLT2i ... mcclaffertyMD #SGLT2
POCUS Echocardiography - Table of Cardiac Views and Windows
 • Parastemal Long-Axis View (PLAX)
 • Parasternal
-Chamber View (A4C ... -Chamber View (A5C ... -Chamber View (A2C ... -Chamber View (A3C ... Echocardiography #Cardiology
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... cardiovascular #renal #SGLT2i
SGLT2 Inhibitors and Euglycemic DKA

Risk factors for euglycemic DKA in those on an SGLT2i include:
 •
SGLT2 Inhibitors ... in those on an SGLT2i ... is closed • SGLT2 ... Kat_Watson #SGLT2
How SGLT2 inhibitors block glucose reabsorption in proximal tubule and improve systemic glucose homeostasis:
https://www.ajkd.org/article/S0272-6386(18)30633-4/fulltext

#Pathophysiology #Mechanism #Nephrology
How SGLT2 inhibitors ... Mechanism #Nephrology #SLGT2
Pathophysiology Euglycemic DKA - Mechanism of SGLT-2 Inhibitors #Pathophys #Endocrine #Euglycemic #DKA #SGLT2 #Mechanism
- Mechanism of SGLT ... Euglycemic #DKA #SGLT2
Diabetes Combination Tablets - Estimated A1c Lowering 
Metformin + DPP4 
• Janumet (metformin + sitagliptin) 
•
Tablets - Estimated A1c ... Metformin + SGLT2 ... dapagliflozin) Dpp4 + SGLT2
#SGLT2i #patientinfo #nephrology
#SGLT2i #patientinfo